![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Dalmane, Dalmadorm, Fluzepam |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682051 |
Pregnancy category |
|
Addiction liability | Moderate |
Routes of administration | By mouth |
Drug class | Benzodiazepine |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 83% |
Metabolism | Liver |
Metabolites | N-desalkylflurazepam (active metabolite) |
Elimination half-life | 2.3 hours N-desalkylflurazepam: 47–100 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.037.795 |
Chemical and physical data | |
Formula | C21H23ClFN3O |
Molar mass | 387.88 g·mol−1 |
3D model (JSmol) | |
Melting point | 79.5 °C (175.1 °F) |
| |
| |
(verify) |
Flurazepam[2] (marketed under the brand names Dalmane and Dalmadorm) is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties. It produces a metabolite with a long half-life, which may stay in the bloodstream for days.[3] Flurazepam was patented in 1968 and came into medical use the same year.[4] Flurazepam, developed by Roche Pharmaceuticals, was one of the first benzodiazepine hypnotic medications to be marketed.[5]
© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search